Cook Medical reports positive two-year data from stent trial

Cook Medical has published encouraging new 24-month data from an ongoing clinical study of its investigational Zilver PTX drug-eluting stent technology.

Two-year results from the trial of the paclitaxel-coated self-expanding nitinol stent shows that primary patency levels achieved using the device were sustained from the rates seen after a one-year analysis.

The study is being conducted among 479 patients and is designed to evaluate the effectiveness of the stent in addressing the symptoms of peripheral arterial disease (PAD).

In addition to these headline results, data from the study also showed that Zilver PTX has achieved an 86.6 percent event-free survival rate after 24 months.

Rob Lyles, global leader and vice-president of Cook Medical's peripheral intervention division, said: "This clinical trial was rigorously designed to lend real-world perspective to the current treatment landscape of PAD and we are excited by the results we have thus far collected."

This week, Cook Medical also reported positive data from its clinical investigation of a balloon-expandable renal stent for the treatment of renal artery stenosis.